Please assess the completion status of the following clinical trial:

Trial Title: Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* One of the following diagnoses:~  1. Chronic myelogenous leukemia (CML) accelerated phase or second stable phase; individuals in the first chronic phase are eligible if they have resistance to imatinib~ 2. Myelodysplasia~ 3. Aplastic anemia that is not responding to immunosuppressive therapy~ 4. Myelofibrosis, either primary or secondary to polycythemia vera~ 5. Relapsed lymphoma or Hodgkin's disease~ 6. Stage III/IV chronic lymphocytic leukemia (CLL), relapsed after or refractory to at least one fludarabine containing regimen~ 7. Acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) in complete remission (CR) 2 or greater, or CR 1 with high risk features~* No prior autologous stem cell transplant~* Eastern Cooperative Oncology Group (ECOG) performance status of less than 2~* Lack of 6/6 or 5/6 matched related donor OR lack of 10/10 matched unrelated donor OR no available donor in the appropriate time frame to perform a potentially curative stem cell transplant~* Diffusing capacity of the lung for carbon monoxide (DLCO) greater than 50% of predicted value~* Left ventricular ejection fraction (LVEF) greater than 50% of predicted value~* Calcium levels less than 10.5 mg/dl~* Phosphate levels greater than 1.6 mg/dl~Exclusion Criteria:~* Heart disease, as determined by symptomatic congestive heart failure, radionuclide ventriculogram (RVG), or echocardiogram-determined LVEF of less than 50%, active angina pectoris, or uncontrolled high blood pressure~* Pulmonary disease, as determined by severe chronic obstructive lung disease, symptomatic restrictive lung disease, or corrected DLCO of less than 50% of predicted value~* Kidney disease, as determined by serum creatinine levels greater than 2.0 mg/dl~* Liver disease, as determined by serum bilirubin levels greater than 2.0 mg/dl (except in the case of Gilbert's syndrome or hemolytic anemia in which the bilirubin can be elevated greater than 2.0mg/dl), SGOT or SGPT greater than 3 times the upper limit of normal~* Neurologic disease, as determined by symptomatic leukoencephalopathy, active central nervous system (CNS) cancer, or other neuropsychiatric abnormalities that may prevent transplantation (previous CNS cancer and presently in CR is acceptable)~* HIV antibodies~* Uncontrolled infection~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Parathyroid Hormone (teriparatide) (Type: EXPERIMENTAL): Parathyroid hormone after double umbilical cord blood transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).